Table 2 Change in renal function and RAAS markers from baseline to end of treatment and follow-up
Parameter, LS mean percentage change (95% CI) | EOT | EOF | ||
|---|---|---|---|---|
Aleglitazar | Pioglitazone | Aleglitazar | Pioglitazone | |
150 μg | 45 mg | 150 μg | 45 mg | |
eGFR | n = 148 | n = 147 | n = 140 | n = 132 |
–15.0† (–19.1, –10.8) | –5.4 (–9.6, –1.2) | –2.7 (–7.7, 2.4) | –3.4 (–8.5, 1.7) | |
SCr | n = 148 | n = 147 | n = 140 | n = 132 |
17.3† (13.1, 21.5) | 6.9 (2.6, 11.1) | 5.4 (1.3, 9.5) | 4.9 (0.7, 9.0) | |
Cystatin-C | n = 148 | n = 147 | n = 140 | n = 130 |
16.1‡ (11.8, 20.4) | 11.4 (7.1, 15.8) | 12.8 (8.7, 16.9) | 14.8 (10.6, 19.1) | |
RAAS markers | ||||
Renin* | n = 138 | n = 138 | n = 135 | n = 127 |
19.9 (–1.8, 46.3) | 31.0 (7.6, 59.5) | 12.9 (–7.4, 37.7) | 14.6 (–5.9, 39.6) | |
Aldosterone* | n = 125 | n = 122 | n = 122 | n = 114 |
–10.8 (–21.8, 1.7) | –11.2 (–22.1, 1.2) | –5.5 (–16.6, 7.1) | 2.1 (–9.8, 15.6) | |
Sodium excretion (fractional)* | n = 143 | n = 139 | n = 139 | n = 130 |
27.1‡ (10.8, 45.9) | 4.6 (–9.0, 20.3) | 0.9 (–12.1, 15.8) | –6.2 (–18.5, 8.0) | |
Renal tubular markers | ||||
α-GST* | n = 96 | n = 96 | n = 84 | n = 84 |
12.7 (0.7, 26.2) | 1.0 (–10.0, 13.3) | 3.9 (–7.6, 16.9) | 6.9 (–5.1, 20.4) | |
NAG* | n = 142 | n = 140 | n = 138 | n = 132 |
12.4 (–7.7, 37.0) | 0.2 (–17.8, 22.3) | 1.7 (–14.4, 20.9) | 6.8 (–10.3, 27.2) | |